Cisternal Neurocysticercosis: A Systematic Review and Meta-Analysis of Therapeutic Efficacy, Safety, and Outcomes

Abstract

Background

Recent studies show potential benefits of albendazole in managing cisternal neurocysticercosis (NCC), which reduces parasitic burden. This systematic review and meta-analysis aim to evaluate the efficacy of albendazole and other pharmacological treatments in cisternal NCC, considering the heterogeneity of disease manifestations and the need for effective treatment strategies.

Methods

Comprehensive searches were conducted across PubMed, Web of Science, Scopus, CENTRAL, and Embase up to March 2024, focusing on RCTs and observational studies that examined albendazole's impact on cisternal NCC. Data were pooled using a random-effects model, adhering to the Cochrane handbook for systematic reviews and meta-analysis and the preferred reporting items for systematic reviews and meta-analyses guidelines, to calculate relative risks (RRs) for various outcomes, including cyst resolution and side effects.

Results

Eight studies with 2,001 patients treated with albendazole, comparing outcomes against placebo or no treatment. Findings indicated a statistically significant decrease in complete cyst resolution among albendazole recipients (RR = 0.69), with notable heterogeneity across studies. No significant differences were observed in persistent cysts, partial cyst resolution, seizures, nonneurological side effects, death, or calcification rates posttreatment. Adjustments for heterogeneity refined some associations, particularly with persistent cysts after excluding specific studies.

Conclusion

Albendazole demonstrates potential in reducing active cysts in cisternal NCC, though its efficacy varies across different clinical outcomes, necessitating personalized treatment approaches. The observed heterogeneity and the variable impact on cyst resolution and seizures underscore the complexity of managing NCC. Further high-quality, large-scale RCTs are essential to solidify these findings and guide treatment protocols, emphasizing the need for multidisciplinary strategies in addressing this challenging condition.

Keywords

neurocysticercosis - albendazole - cisternal NCC - systematic review - meta-analysis

Publication History

Received: 20 February 2025

Accepted: 24 June 2025

Article published online:
12 July 2025

• References

• 1 Garcia HH, Del Brutto OH. Cysticercosis Working Group in Peru. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005; 4 (10) 653-661
• 2 Garcia HH, Evans CAW, Nash TE. et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002; 15 (04) 747-756
• 3 Singhi P, Dayal D, Khandelwal N. One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J 2003; 22 (03) 268-272
• 4 Gogia S, Talukdar B, Choudhury V, Arora BS. Neurocysticercosis in children: clinical findings and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial in newly diagnosed cases. Trans R Soc Trop Med Hyg 2003; 97 (04) 416-421
• 5 Cruz I, Cruz ME, Carrasco F, Horton J. Neurocysticercosis: optimal dose treatment with albendazole. J Neurol Sci 1995; 133 (1-2): 152-154
• 6 McCormick GF. Cysticercosis–review of 230 patients. Bull Clin Neurosci 1985; 50: 76-101
• 7 Martínez HR, Rangel-Guerra RA, nzález-Gutiérrez O. et al. Exploring albendazole's efficacy in neurocysticercosis management. J Clin Neurol 2020; 16 (04) 556-564
• 8 Garcia HH, Pretell EJ, Gilman RH. et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004; 350 (03) 249-258
• 9 Smith JL, Anderson CP, Patel RM, White Jr AC, Tanowitz HB. Albendazole in neurocysticercosis: a review of clinical efficacy and safety. Pharmacotherapy 2018; 38 (09) 914-922
• 10 Thompson BN, Rivera MA, Delgado JC, Núñez LM, Soto DM, Ríos CA. Impact of early intervention on outcomes in neurocysticercosis: a longitudinal study. Neurol Sci 2019; 40 (02) 345-353
• 11 Lee DY, Kim SJ, Cho YJ, Lee SK, Kim JY. Long-term outcomes of albendazole therapy in patients with neurocysticercosis. Clin Infect Dis 2021; 72 (10) e441-e449
• 12 Padma MV, Behari M, Misra NK, Ahuja GK. Albendazole in neurocysticercosis. Natl Med J India 1995; 8 (06) 255-258
• 13 Salinas R, Counsell C, Prasad K, Gelband H, Garner P. Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. Trop Med Int Health 1999; 4 (11) 713-718
• 14 Alarcón F, Escalante L, Dueñas G, Montalvo M, Román M. Neurocysticercosis. Short course of treatment with albendazole. Arch Neurol 1989; 46 (11) 1231-1236
• 15 Das K, Mondal GP, Banerjee M, Mukherjee BB, Singh OP. Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study. J Clin Neurosci 2007; 14 (12) 1172-1177
• 16 Carpio A, Kelvin EA, Bagiella E. et al. Ecuadorian Neurocysticercosis Group. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008; 79 (09) 1050-1055
• 17 Thussu A, Chattopadhyay A, Sawhney IM, Khandelwal N. Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. Journal of Neurology, Neurosurgery & Psychiatry 2008; Mar 1; 79 (03) 272-275
• 18 Khurana N, Sharma P, Shukla R. et al. Midbrain neurocysticercosis presenting as isolated pupil sparing third cranial nerve palsy. J Neurol Sci 2012; 312 (1-2): 36-38
• 19 Gulati S, Jain P, Sachan D. et al. Seizure and radiological outcomes in children with solitary cysticercous granulomas with and without albendazole therapy: a retrospective case record analysis. Epilepsy research 2014; 108 (07) 1212-1220